This enduring recording from the ASCP 2025 Annual Meeting focuses on optimizing non-small cell lung cancer (NSCLC) biomarker testing. The session reviews emerging biomarkers and evolving targeted therapy considerations, clarifies the roles of key testing modalities (e.g., IHC, ISH, and NGS), and highlights practical strategies to improve tissue stewardship, specimen adequacy, and pre-analytic processes to support timely, appropriate, and equitable testing across clinical settings.
Course topics include:
- NSCLC biomarker testing overview
- HER2 (ERBB2) and MET/c-Met in NSCLC
- Testing methods: IHC, ISH (FISH/CISH), and NGS
- Specimen workflow and tissue stewardship
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
Learning Objectives
Upon completion of this activity, you will be able to:
- Discuss the latest research in new and emerging biomarkers for NSCLC
- Prepare for potential changes to biomarker testing workflows as new therapies for patients with advanced NSCLC emerge
- Outline the role of different HER2 testing methods in NSCLC to identify overexpression, amplification, and mutations
- Apply current practice guidelines for biomarker testing in patients with NSCLC
- Optimize NSCLC specimen protocols to ensure sufficient sample sizes for biomarker testing
Faculty
Ying-Chun Lo, M.D., Ph.D.,
Associate Professor and Consultant and Divisions of Anatomic Pathology and Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Mamatha Chivukula, MD, FASCP
Sutter Health, San Francisco, California
Jeffree Schulte
Associate Professor and Director of Surgical Pathology, Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI
Joseph Kim, MD, MPH, MBA, FACHE
President, Q Synthesis LLC, Langhorne, PA
Faculty Disclosures
Dr. Chivukula, Dr. Schulte, and Dr. Kim have no financial relationships to disclose. All relevant financial relationships for Dr. Lo have been mitigated.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)â„¢. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of 1.o CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.
Method of Participation
To complete the activity and receive credit, the participant must participate in the online activity. CME certificates will be provided online.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.